51³Ô¹ÏÍø

Tag - donanemab

 
 

DONANEMAB

A team of researchers said they found a ¡°seed¡± that accelerates the amyloid beta accumulation process in the brain, naming it ¡°Peak 1 amyloid beta,¡± as seen in a mouse's brain.
51³Ô¹ÏÍø / Science & Health
Jul 21, 2026
Japan scientists identify clusters of protein believed to trigger Alzheimer¡¯s disease
The discovery of a new seed of the amyloid beta protein could lead to early-stage therapy for neurodegenerative disease, according to researchers.
Lecanemab and donanemab aim to slow the progression of the neurodegenerative disease by removing a protein called amyloid-beta from the brain, whose buildup is believed to contribute to the death of brain cells.
51³Ô¹ÏÍø / Science & Health
Apr 8, 2026
Less than 20% of patients in Japan interested in new Alzheimer¡¯s drugs received one
Many were ineligible or decided against taking the medications due to potential side effects and the high cost, a study has found.
A scientist looks at scans of brains at the Memory Centre, part of the Department of Readaptation and Geriatrics at the University Hospital of Geneva (HUG), in 2023.
51³Ô¹ÏÍø / Science & Health / FOCUS
Sep 17, 2025
Japan¡¯s front-line researchers see bright path ahead for dementia treatment
Four scientists at the forefront of dementia research speak about what kind of future they envision for people with the condition.
For patients using donanemab, it will cost them about ?3.08 million per year. But national insurance coverage will have the government shoulder most of the cost.
51³Ô¹ÏÍø / Science & Health
Nov 13, 2024
Japan OKs insurance coverage of Alzheimer¡¯s drug donanemab
Donanemab became the second Alzheimer¡¯s drug that targets causative deposited plaque in the brain to win the coverage after lecanemab.
A scientist looks at brain scans of a patient suffering from Alzheimer's disease in Geneva in 2023.
WORLD / Science & Health
Sep 21, 2024
Revolution or mirage? Controversy surrounds new Alzheimer¡¯s drugs
For defenders, the drugs represent a real chance to fight the disease. For detractors, they are a disappointment after a long line of costly failures.
A health ministry panel has approved Eli Lilly's donanemab drug for Alzheimer's patients.
51³Ô¹ÏÍø / Science & Health
Aug 2, 2024
Japan¡¯s health ministry set to approve second Alzheimer¡¯s drug
Donanemab, developed by U.S. pharmaceutical firm Eli Lilly, has been backed by a ministry panel.

Longform

For many people, utility poles and power lines have become such a familiar part of Japan¡¯s landscape that they often go unnoticed.
Why Japan¡¯s utility poles won¡¯t be disappearing anytime soon

SUSTAINABLE 51³Ô¹ÏÍø